Market capitalization | $7.38m |
Enterprise Value | $1.09b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 73.99 |
EV/Sales (TTM) EV/Sales | 1.05 |
P/S ratio (TTM) P/S ratio | 0.01 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -2.68% |
Revenue (TTM) Revenue | $1.04b |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Exela Technologies, Inc.:
1 Analyst has issued a forecast Exela Technologies, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 1,038 1,038 |
3%
3%
|
|
Gross Profit | 171 171 |
9%
9%
|
|
EBITDA | 68 68 |
36%
36%
|
EBIT (Operating Income) EBIT | 12 12 |
72%
72%
|
Net Profit | -100 -100 |
66%
66%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Exela Technologies, Inc. engages in the provision of transaction processing solutions and enterprise information management. It operates through the following segments: Information and Transaction Processing Solutions, Healthcare Solutions, and Legal and Loss Prevention Services. The Information and Transaction Processing Solutions segment provides industry-specific solutions for banking and financial services. The Healthcare Solutions segment offers revenue cycle solutions, integrated accounts payable and accounts receivable, and information management for both the healthcare payer and provider markets. The Legal and Loss Prevention Services segment includes processing of legal claims for class action and mass action settlement administrations, involving project management support, notification, and outreach to claimants; and collection, analysis, and distribution of settlement funds. The company was founded on July 15, 2014 and is headquartered in Irving, TX.
Head office | United States |
CEO | Suresh Yannamani |
Employees | 14,100 |
Founded | 2004 |
Website | www.exelatech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.